Astrana Health’s second quarter was met with a positive market response, as management highlighted several drivers behind the results. The company saw continued demand from payer and provider partners, maturation of value-based care cohorts, and disciplined medical cost trend management. CEO Brandon Sim attributed operating leverage improvements to the company’s proprietary AI-native healthcare operating system, which has enabled more efficient workflows and reduced general and administrative expenses. The integration of the Prospect Health acquisition also contributed to overall performance, with gross provider retention above 99% and expected operating expense synergies at the high end of targeted ranges.
Is now the time to buy ASTH? Find out in our full research report (it’s free for active Edge members).
Astrana Health (ASTH) Q2 CY2026 Highlights:
- Revenue: $972.5 million vs analyst estimates of $985.4 million (48.5% year-on-year growth, 1.3% miss)
- Adjusted EPS: $0.80 vs analyst estimates of $0.73 (9.6% beat)
- Adjusted EBITDA: $68.89 million vs analyst estimates of $67.93 million (7.1% margin, 1.4% beat)
- The company reconfirmed its revenue guidance for the full year of $3.95 billion at the midpoint
- EBITDA guidance for the full year is $267.5 million at the midpoint, in line with analyst expectations
- Operating Margin: 3.5%, in line with the same quarter last year
- Market Capitalization: $1.83 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Astrana Health’s Q2 Earnings Call
- Matthew Mardula (William Blair): Asked about current cost trends and commercial segment pressures; CEO Brandon Sim explained that overall trends are slightly better than assumed, with commercial costs above expectations but manageable and not requiring guidance changes.
- Jack Slevin (Jefferies): Inquired on Medicare Advantage bid alignment and future upside; Sim noted confidence in continued MA success and highlighted opportunities for improved coding and stable inpatient trends.
- Michael Ha (Baird): Sought details on transitioning Medi-Cal members to full risk and the expected earnings impact; Sim shared that tens of thousands of members will move to full risk, aligning financial incentives, though precise economics were not disclosed.
- Jailendra Singh (Truist): Asked about fourth quarter EBITDA guidance range and medium-term growth; Sim attributed Q4 seasonality to typical patterns and reaffirmed mid-to-high teens EBITDA growth targets, factoring in Medicaid headwinds and ongoing investments.
- Matthew Gillmor (KeyBanc Capital Markets): Queried the nature and benefit of automated member encounters; Sim described varied automated interactions supporting care delivery and G&A reduction, emphasizing long-term potential for AI-driven cost improvements.
Catalysts in Upcoming Quarters
Looking ahead, our analyst team will be closely monitoring (1) the pace and profitability of transitioning more Medicaid and exchange members to full risk arrangements, (2) incremental contributions from new Medicare Advantage contracts in expansion markets like Texas and Hawaii, and (3) continued realization of operating expense synergies from the Prospect Health integration. Progress in scaling AI-enabled automation across administrative and clinical workflows will also be a key indicator of execution.
Astrana Health currently trades at $36.09, up from $34.13 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
